维格列汀联合门冬胰岛素30注射液对肥胖型2型糖尿病患者胰岛β细胞功能及血清糖化血红蛋白水平的影响

Abstract
Figure/Table
References
Related Citation (5)

Download: PDF (697 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of vildagliptin + insulin aspart 30 injection on islet β-cell function, serum glycosylated hemoglobin (HbA₁c) and vaginal adipose tissue-derived serine protease inhibitor (VASPIN) in obese type 2 diabetic patients.Methods A total of 157 patients with obese type 2 diabetes mellitus treated between March 2017 and July 2018 were enrolled in this study. Using the random number table method, these patients were divided into the control group (n=78) and study group (n=79). The control group was injected with insulin aspart 30, while the study group was additionally treated with vildagliptin. The course of treatment was 12 weeks. The curative effect and rate of adverse reactions were compared between the two groups. The fasting blood glucose (FPG), postprandial 2 h blood glucose (2 h PG), HbA1c, islet β cell secretory index (HOMA-β) and VASPIN levels before and after treatment were compared.Results (1) The ideal rate of HbA₁c control in the study group was higher than that in the control group (P<0.05). (2) The levels of FPG, 2 h PG and HbA₁c in the two groups were lower after treatment, especially in the study group (P<0.05). (3) The levels of serum HOMA-β and VASPIN in the two groups were higher after treatment, particularly in the study group (P<0.05). (4) The total incidence of adverse reactions in the study group was 5.06%, which was not significantly different from the control group (2.56%) (P>0.05).Conclusions The treatment of obese type 2 diabetic patients with vildagliptin + insulin aspart 30 injection is obviously effective, which can improve their blood glucose and serum VASPIN levels, protect islet β cell function, and reduce the incidence of hypoglycemia.

Key words： vildagliptin insulin aspart 30 injection obese type 2 diabetes islet β cell function glycated hemoglobin visceral adipose tissue-derived serine protease inhibitor

Received: 10 November 2018

ZTFLH:

R587.1

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Rui
	JIN Xiaona
	ZHANG Dangfeng

Cite this article:

LI Rui,JIN Xiaona,ZHANG Dangfeng. Effect of vildagliptin combined with insulin aspart 30 injection on islet β-cell function and serum HbA1c and VASPIN levels in obese type 2 diabetic patients[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2019, 30(6): 499-502.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2019/V30/I6/499

[1]	Pan C,Xing X,Han P,et al.Efficacy and tolerability of vild agliptin as add - on therapy to metforminin Chinese patients with type 2diabetes mellitus[J].Diabetes Obes Metab,2012,14(8):737-744.
[2]	陈茂胜,田浩明.二甲双胍联合维格列汀治疗肥胖型2型糖尿病的临床观察[J].现代药物与临床,2014,29(5):503-507.
[3]	Derosa G,Maffioli P. Efficacy and safety profile evaluation of acarbose alone and in association with other antidiabetic drugs: asystematic review[J].Clin Ther,2012,34(6):1221-1236.
[4]	赵晓伟,田坚,沈静雪,等.维格列汀对经二甲双胍治疗的肥胖型2型糖尿病患者肺功能的影响[J].安徽医药,2016,20(2):369-373.
[5]	辛彩虹,李峥,洛伟光,等.维格列汀联合二甲双胍对超重2型糖尿病患者心血管疾病危险因素的干预作用[J].解放军医药杂志,2015,12(8):83-87.
[6]	徐小华,胡蕴,苏晓飞,等.维格列汀对磺脲类药物继发性失效的2型糖尿病患者的疗效[J].江苏医药,2016,42(18):1975-1977.
[7]	中华医学会糖尿病学分会.中国2型糖尿病防治指南(2013年版)[J].中国糖尿病杂志,2014,30(8):893-942.
[8]	邓海鸥,林凯,黎映兰,等.阿卡波糖联合维格列汀治疗老年2型糖尿病患者的效果及安全性[J].广东医学,2015,36(12):1928-1929.
[9]	Su J B,Wang X Q,Chen J F,et al.Glycemic variability in insulin treated type 2 diabetes with well-controlled hemoglobin A1c and its response to further treatment with acarbose[J].Chin Med J(Engl),2011,124(1):144-147.
[10]	马淑肖.维格列汀联合二甲双胍与胰岛素强化治疗初诊2型糖尿病患者的对比研究[J].山西医药杂志,2016,45(5):565-567.
[11]	Choe E Y,Cho Y,Choi Y,et al.The effect of DPP-4 inhibitors on metabolic parameters in patients with type 2 diabete[J].Diabetes Metab J,2014,38(3):211-219.
[12]	李睿,王会仓,刘美建.维格列汀联合二甲双胍对新诊断2型糖尿病患者胰岛β细胞功能和胰岛素抵抗的改善作用[J].现代中西医结合杂志,2016,25(23):2575-2577.
[13]	单春艳,孔岩,殷明亮,等.胰岛素联合维格列汀治疗2型糖尿病合并中度肾损伤患者的有效性和安全性[J].中国糖尿病杂志,2014,6(5):321-324.
[14]	程佳媛,白雪琴,王春光,等.维格列汀对2型糖尿病合并冠心病患者血清脂联素、抵抗素水平的影响[J].现代中西医结合杂志,2015,24(32):3546-3548.
[15]	许翎,林凯,邓海鸥,等.维格列汀联合门冬胰岛素治疗老年2型糖尿病患者的疗效及安全性[J].南方医科大学学报,2014,34(10):1515-1518.
[16]	Strain W D,Lukashevich V,Kothny W,et al.Individualised treatment targets for elderly patients with type 2 diabetes using vildagliptin add-on or lone therapy(INTERVAL):a 24 week, randomised, doubleblind,placebo-controlled study[J].Lancet,2013,382(9890):409-416.
[17]	彭莉,马俊花,尤文,等.维格列汀片对 T2 DM 患者血清尿液淀粉酶水平的影响[J].河北医学,2014,20(5):723-726.
[18]	潘宇.维格列汀联合门冬胰岛素30注射液治疗老年2型糖尿病的疗效分析[J].中国慢性病预防与控制,2015,23(2):139-140.
[19]	朱鸿玲,王菁楠,尤文,等.二甲双胍联合维格列汀治疗初诊2型糖尿病的疗效及对血糖波动的影响[J].临床和实验医学杂志,2016,15(11):1078-1081.
[20]	闫赋琴,徐春.DPP4抑制药对2型糖尿病患者的血糖、血脂、胰岛素、瘦素、SAA和白细胞介素的影响[J].临床和实验医学杂志,2016,15(24):2426-2429.